What is the official website of ViiV Healthcare ?

The official website of ViiV Healthcare is http://www.viivhealthcare.com.

What is ViiV Healthcare's cybersecurity risk score?

ViiV Healthcare has an AI-generated cybersecurity risk score of 763 out of 1000, indicating a Fair security posture according to Rankiteo's assessment.

How many security incidents has ViiV Healthcare experienced?

According to Rankiteo, ViiV Healthcare currently holds 0 security badges, indicating that no recognized compliance certifications are currently verified for the organization.

Has ViiV Healthcare been affected by any supply chain cyber incidents ?

According to Rankiteo, ViiV Healthcare has not been affected by any supply chain cyber incidents, and no incident IDs are currently listed for the organization.

Does ViiV Healthcare have SOC 2 Type 1 certification ?

According to Rankiteo, ViiV Healthcare is not certified under SOC 2 Type 1.

Does ViiV Healthcare have SOC 2 Type 2 certification ?

According to Rankiteo, ViiV Healthcare does not hold a SOC 2 Type 2 certification.

Does ViiV Healthcare comply with GDPR ?

According to Rankiteo, ViiV Healthcare is not listed as GDPR compliant.

Does ViiV Healthcare have PCI DSS certification ?

According to Rankiteo, ViiV Healthcare does not currently maintain PCI DSS compliance.

Does ViiV Healthcare comply with HIPAA ?

According to Rankiteo, ViiV Healthcare is not compliant with HIPAA regulations.

Does ViiV Healthcare have ISO 27001 certification ?

According to Rankiteo,ViiV Healthcare is not certified under ISO 27001, indicating the absence of a formally recognized information security management framework.

Which industry does ViiV Healthcare operate in ?

ViiV Healthcare operates primarily in the Pharmaceutical Manufacturing industry.

How many employees does ViiV Healthcare have ?

ViiV Healthcare employs approximately 1,879 people worldwide.

Does ViiV Healthcare own any subsidiaries ?

ViiV Healthcare presently has no subsidiaries across any sectors.

How many LinkedIn followers does ViiV Healthcare have ?

ViiV Healthcare's official LinkedIn profile has approximately 96,420 followers.

What is the NAICS classification code for ViiV Healthcare ?

ViiV Healthcare is classified under the NAICS code 3254, which corresponds to Pharmaceutical and Medicine Manufacturing.

Does ViiV Healthcare have a Crunchbase profile ?

No, ViiV Healthcare does not have a profile on Crunchbase.

Does ViiV Healthcare have a LinkedIn profile ?

Yes, ViiV Healthcare maintains an official LinkedIn profile, which is actively utilized for branding and talent engagement, which can be accessed here: https://www.linkedin.com/company/viiv-healthcare.

How many cybersecurity incidents has ViiV Healthcare experienced ?

As of July 31, 2026, Rankiteo reports that ViiV Healthcare has not experienced any cybersecurity incidents.

How many peer or competitor companies does ViiV Healthcare have ?

ViiV Healthcare has an estimated 5,720 peer or competitor companies worldwide.

NEWRankiteo Cyber Underwriting Desktop - Score, price, and bind from your desktop

WindowsmacOSLinux

Download

Badge your company to reduce your risk score and your cyber insurance costs!

Link verified badges to your company page to build trust with insurers and customers.

Apply now and get your badge!

Internal validation & live display

Insurers and partners see a safer profile

Faster underwriting decisions

Trusted by insurers. Chosen by leaders.

Proud contributor to the Society of Actuaries.

ViiV Healthcare

Boost Score +25 with badge (5 left)

763

/1000

Fair

788

/1000

Fair

ViiV Healthcare Vendor Cyber Rating & Cyber Score

viivhealthcare.com

Add Your Compliance Badge

We are ViiV Healthcare: the only global pharmaceutical company 100% dedicated to preventing, treating and curing HIV. Unafraid to be first, we push the boundaries of what people think is possible – bringing together our transformational science and a deep understanding of the communities we serve – all to reach a HIV-free generation and ultimately, make HIV history. For job opportunities, please visit the ViiV careers page: https://viivhealthcare.com/viiv-careers/ Read our Social Media Code of Conduct: bit.ly/SoMe-VHC

ViiV Healthcare A.I CyberSecurity Scoring

Scoring History

ViiV Healthcare

ViiV Healthcare CyberSecurity News & History

Past Incidents

Attack Types

Entity

Type

Severity

Impact

Seen

Blog Details

Supply Chain Source

Incident Details

View

No data available

Loading…

A.I.

ViiV Healthcare Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Actual

Prediction

Incident Predictions locked

Access Monitoring Plan

A.I Risk Score Likelihood 3 - 6 - 9 months

Actual

Prediction A

Prediction B

Prediction C

Prediction D

A.I. Risk Score Predictions locked

Access Monitoring Plan

Loading…

Underwriter Stats for ViiV Healthcare

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for ViiV Healthcare in 2026.

Incidents vs All-Companies Average (This Year)

No incidents recorded for ViiV Healthcare in 2026.

Incident Types ViiV Healthcare vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for ViiV Healthcare in 2026.

Incident History - ViiV Healthcare (X = Date, Y = Severity)

Loading…

SUBSIDIARY

ViiV Healthcare Subsidiaries

ViiV Healthcare

Pharmaceutical Manufacturing

Website: http://www.viivhealthcare.com

Company Size: 1,879

GSKPharmaceutical Manufacturing

GSK ItaliaPharmaceutical Manufacturing

Loading…

ViiV Healthcare Similar Companies

Torrent Pharmaceuticals Ltd

cb torrentpharma.com

Torrent Pharma, with annual revenues of more than Rs 10,700 crores, is the flagship Company of the Torrent Group, with group revenues of Rs 41,000 crores. It is ranked 5th in the Indian Pharma Market and is among the Top 5 in the therapeutic segments of Cardiovascular (CV), Central Nervous System (CNS), Gastro-intestinal (GI), Vitamins Minerals Nutritionals (VMN) and Cosmo-Dermatology. The Company also has significant presence in diabetology, pain management, gynaecology, oncology and anti-infective segments. Torrent has 8 manufacturing facilities , of which 5 are USFDA approved. With R&D as the backbone for its growth in domestic & overseas market, it has invested significantly in R&D capabilities with state-of-the-art R&D infrastructure employing around 800 scientists. The acquisition of Elder Pharma's Indian branded business in 2013, Dermaceuticals business of Zyg Pharma in 2015, API plant of Glochem Industries in 2016, Women healthcare brands from Novartis and Unichem's Indian branded business along with its Sikkim Plant in 2017 strengthened Torrent Pharma's position in the Indian Pharma market. Torrent Pharma started international acquisitions in 2005 with entry into the German market. Today, the Company has presence in more than 50 countries and is ranked No. 1 among the Indian pharma Companies in Brazil and Germany. Torrent Pharma is committed towards “not just healthcare but lifecare.”

Lupin

lupin.com

Lupin Limited is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. Lupin specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. Trusted by healthcare professionals and consumers globally, the company enjoys a strong position in India and the U.S. across multiple therapy areas, including respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system, and women’s health. Lupin has 15 state-of-the-art manufacturing sites and 7 research centers globally, along with a dedicated workforce of over 23,000 professionals. Lupin is committed to improving patient health outcomes through its subsidiaries – Lupin Diagnostics, Lupin Digital Health, and Lupin Manufacturing Solutions.

Fresenius Kabi

fresenius-kabi.com

As a global healthcare company, Fresenius Kabi is Committed to Life. The company’s products, technologies, and services are used for the therapy and care of critically and chronically ill patients. With over 41,000 employees and present in over 100 countries, Fresenius Kabi’s expansive product portfolio focuses on providing access to high-quality and lifesaving medicines and technologies. In Biopharma, Fresenius Kabi offers cutting-edge biosimilars for autoimmune diseases and oncology. With leading market positions in Clinical Nutrition, a broad portfolio of enteral and parenteral products makes a distinct difference in patients’ nutritional status. In MedTech, the company provides vital infusion pumps, cell and gene therapy devices, disposables, and more. Fresenius Kabi is the global leader in supplying blood collection bags and devices, supporting blood banks and healthcare facilities worldwide. The company’s I.V. Generics and Fluids for infusion therapy help save millions of lives every year, in emergency medicine, surgery, oncology, and intensive care. Fresenius Kabi takes a holistic approach to healthcare and uniquely combines experience, expertise, innovation, and dedication – making a difference in the lives of 450 million patients annually. With the #FutureFresenius strategy, the company is developing, producing, and selling new products and technologies and aspires to expand its position as a leading global provider of therapies, improve patient care, generate sustainable value for stakeholders – shaping the future of healthcare. Fresenius Kabi is an operating company of the Fresenius Group, founded in 1912, along with Helios and Quirónsalud. As ONE team, the companies in the Fresenius Group are committed to providing lifesaving and life-changing healthcare solutions on a global scale. User information & community guidelines: https://www.fresenius-kabi.com/social-media-terms-conditions Imprint: www.fresenius-kabi.com/imprint

Parexel

parexel.com

Parexel is a leading global clinical research organization (CRO) providing insights-driven Clinical and Consulting solutions to the world’s life sciences industry. Leveraging deep local knowledge and a global breadth of clinical, regulatory and therapeutic expertise, our 24,000+ professionals worldwide work in partnership with biopharmaceutical leaders, emerging innovators and sites to design and deliver clinical trials with patients in mind — broadening access and making clinical research a care option for anyone, anywhere. Our proven track record spans 40+ years and drives us forward, advancing clinical research in healthcare’s most complex areas while harnessing innovation to drive efficiencies across every phase of the clinical development process. Our insights-driven approach, proven delivery and trusted execution are accelerating the delivery of life-changing treatments to patients — With Heart.™ We continue to earn recognition industrywide, including the 2025 Scrip Award for “Best Contract Research Organization – Full-Service Provider,” 2024 Fierce Biotech CRO Award for "Innovative Approaches to Patient-Centric Research" and the 2024 and 2023 Society for Clinical Research Sites (SCRS) Eagle Award. Community Guidelines Because Parexel’s social media channels are open to the general public and employees, we are not responsible for views expressed other than our own. However, we do not tolerate posts that are: • Abusive, harassing or threatening to others. • Defamatory, offensive, obscene, vulgar or depicting violence. • Hateful targeting by race/ethnicity, age, color, creed, religion, gender, sexual preference or orientation, nationality or political beliefs. • Sexually explicit or pornographic. • Fraudulent, deceptive, libelous, misleading or unlawful. • Referencing criminal or illegal activity. • Spamming. We reserve the right to remove comments that do not adhere to our guidelines and report users who violate the rules of our page.

Zydus Group

zyduslife.com

The Zydus Group with an overarching purpose of empowering people with freedom to live healthier and more fulfilled lives, is an innovative, global life-sciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies. The group employs over 27000 people worldwide and is driven by its mission to unlock new possibilities in life-sciences through quality healthcare solutions that impact lives. The group aspires to transform lives through pathbreaking discoveries.

Bristol Myers Squibb

cb bms.com

At Bristol Myers Squibb, we work every day to transform patients’ lives through science. That work inspires some of the most interesting, meaningful, and life-changing careers you’ll experience. Join us and pursue innovative ideas alongside some of the brightest minds in biopharma, collaborating with a team rich in diversity of experiences, and perspectives. We have built a sustainable pipeline of potential therapies and are leveraging translational medicine and data analytics to understand how we can deliver the right medicine to the right patient, at the right time, to achieve the best outcome. Whether in a scientific, business or supporting function, a career at BMS means you’ll be inspired every day to grow and thrive through opportunities that are uncommon in scale and scope. Here, you’ll be on the cutting edge of powerful innovation in oncology, hematology, immunology, cardiovascular disease, and fibrosis, with colleagues united in the mission to help patients. Through the Bristol Myers Squibb Foundation, we also promote health equity and seek to improve health outcomes of populations disproportionately affected by serious diseases and conditions. Our mission is to give new hope to help patients prevail over serious disease – it drives everything we do. Review our Social Media Community Guidelines at: https://www.bms.com/social-media-community-guidelines.html

MENARINI Group

menarini.com

The Menarini Group is a leading international pharmaceutical and diagnostics company, present in 140 countries worldwide, with a turnover of 4,37 Billion euro and more than 17,000 employees. With 9 centers for Research & Development, Menarini’s products are present in the most important therapeutic areas, including cardiology, oncology, gastroenterology, pneumology, infectious diseases, diabetes, and anti-inflammatory/analgesics. The Group’s pharmaceutical production is carried out in its 18 manufacturing plants, which produce over 609 million packets of product a year and distribute them to five continents. Menarini’s pharmaceutical production, in line with the highest quality standards, provides an ongoing contribution to the health of patients all over the world. For further information, please visit www.menarini.com For reading our Netiquette, please visit https://www.menarini.com/en-us/data-privacy/netiquette-of-menarini-group For reading our Privacy Notice for social networks users, please visit https://www.menarini.com/en-us/data-privacy/privacy-notice-for-social-network-users-of-menarini-group

Cipla

cipla.com

Cipla is a leading global pharmaceutical company trusted by healthcare professionals and patients across the world since 1935. A compassionate approach to healthcare that goes beyond the pursuit of profit and growth has been the force impelling Cipla’s history over the years. Our credo and our purpose of ‘Caring for Life' continues to guide our actions towards our people and the planet for creating a sustainable future. Cipla today has presence in 80+ countries, providing over 1,500 products across various therapeutic categories in 50+ dosage forms. Keeping with our legacy of care, we constantly strive to ensure access to high-quality medicines that make a difference in the lives of patients. Our paradigm-changing offer of a triple anti-retroviral (ARV) therapy in HIV/AIDS at less than a dollar a day in Africa in 2001 was pivotal in bringing inclusiveness, accessibility and affordability to the centre of the HIV movement. An unmatched presence across the care continuum (awareness, prevention, diagnosis, treatment and adherence) and the widest range of drug-device combinations has established Cipla’s respiratory leadership in India and other key emerging markets. Armed with this legacy and a deep understanding of the lungs, we have articulated our aspiration to become a global lung leader and help millions breathe free.

EMS

cb ems.com.br

Fundada há mais de 60 anos e com capital 100% nacional, a EMS é a líder do mercado farmacêutico brasileiro há 19 anos consecutivos, pertencente ao Grupo NC, um dos maiores conglomerados brasileiros. A empresa ocupa também a liderança no segmento de genéricos desde 2013 (IQVIA 2019) e está entre os maiores laboratórios em preferência prescritiva no Brasil. Tem forte presença em PDVs de todo o país e atuação nas áreas de Prescrição Médica, Genéricos, Marcas, OTC e Hospitalar, fabricando medicamentos para praticamente todas as especialidades da Medicina. Possui fábricas em Hortolândia (SP), Manaus (AM), Brasília (DF) e Jaguariúna (SP). A EMS apoia ações de responsabilidade social dentro e fora do Brasil. Em 2017, por exemplo, o laboratório fechou parceria com a Organização Mundial da Saúde (OMS) para doar 100% do medicamento para erradicar, nos próximos anos, em todo o planeta, a bouba, doença negligenciada. A EMS é a única farmacêutica no mundo a ter abraçado essa causa. O Centro de Pesquisa & Desenvolvimento da EMS no Brasil é o mais moderno da América Latina. Na Itália, a EMS tem o laboratório de pesquisas MonteResearch. O foco de atuação do laboratório é a inovação nas seguintes frentes: inovação incremental; genéricos de alta complexidade; medicamentos biotecnológicos, por meio da empresa Bionovis; e inovação disruptiva, por meio da Brace Pharma, empresa da EMS instalada em 2013 nos Estados Unidos. Ainda, nos EUA, por meio de sua controlada Vero Biotech, localizada em Atlanta, Geórgia, a EMS, recentemente, obteve a aprovação de seu primeiro produto revolucionário submetido à FDA (Food and Drug Administration), posicionando o laboratório como uma empresa de inovação no mercado global. Com aportes frequentes em infraestrutura fabril e em pesquisa de ponta para desenvolver produtos inovadores, eficazes e seguros, a EMS, que já exporta para mais de 40 países, está preparada para continuar cuidando das pessoas que querem viver cada vez mais e melhor.

Loading…

NEWS

ViiV Healthcare CyberSecurity News

Latest updates, reports, and threat intel affecting the global network.

February 26, 2026 08:00 AM

ViiV’s four-monthly HIV drug maintains viral suppression at 12 months

ViiV Healthcare has reported several successful HIV trials at CROI 2026, including its investigational candidates lotivibart,...

Read Article

February 25, 2026 08:00 AM

ViiV Healthcare presents pipeline data for two investigational HIV treatment therapies with potential for twice-yearly dosing

LONDON, February 25, 2026--ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as...

Read Article

February 25, 2026 08:00 AM

ViiV Healthcare reports positive 12-month data showing investigational bNAb lotivibart (N6LS) maintains high levels of viral suppression in long-acting HIV treatment regimen

LONDON, February 25, 2026--ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as...

Read Article

February 18, 2026 08:00 AM

ViiV Healthcare’s long-acting Cabenuva (cabotegravir + rilpivirine) for HIV demonstrates superior efficacy compared to daily oral therapy for people with adherence challenges; results published in NEJM

LONDON, February 18, 2026--ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as...

Read Article

February 17, 2026 08:00 AM

ViiV Healthcare showcases long-acting HIV innovation and potential of ultra long-acting pipeline, including new data for first third-generation integrase inhibitor at CROI 2026

LONDON, February 17, 2026--ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as...

Read Article

January 25, 2026 08:00 AM

Pfizer to Exit ViiV Healthcare as GSK and Shionogi Reshape Ownership

Pfizer Inc. (NYSE:PFE) is included among Dividend Contenders List: Top 20 Stocks. Reuters reported on January 20 that Britain's GSK and...

Read Article

January 20, 2026 08:00 AM

Shionogi expands ViiV Healthcare stake by $2.13bn as Pfizer sells up

Pfizer exits ViiV Healthcare with a $1.89bn payout, while GSK retains its majority stake amid the shareholder shake-up.

Read Article

January 20, 2026 08:00 AM

Pfizer to exit ViiV Healthcare in $1.9 billion deal as Shionogi doubles stake

Britain's GSK and Japan's Shionogi said on Tuesday that Pfizer will exit their HIV specialist ViiV Healthcare in a deal that pays the U.S....

Read Article

December 01, 2025 08:00 AM

Viiv Healthcare : How AI Can Transform African Healthcare

Dr Serufusa Sekidde, Chief of Staff to the CEO at Viiv Healthcare, speaks to the growing importance of artificial intelligence in healthcare...

Read Article

Loading…

CVE

Latest

Global CVEs (Not Company-Specific)

CVE-2026-66720

SUMMARY

The GOOSE subscriber component improperly validates the UTC timestamp field in unauthenticated IEC 61850 GOOSE (EtherType 0x88B8) Layer-2 multicast messages. A specially crafted GOOSE frame containing an undersized timestamp field can trigger a heap out-of-bounds read during message processing, causing the process to crash and resulting in a denial-of-service condition.

Published

Date2026-07-30

Updated

Date2026-07-30

RISK INFORMATION (Score: 6.5)

cvss3

Base Score: 6.5

Complexity: LOW

CVSS:3.1/AV:A/AC:L/PR:N/UI:N/S:U/C:N/I:N/A:H

cvss4

Base Score: 7.1

Complexity: LOW

CVSS:4.0/AV:A/AC:L/AT:N/PR:N/UI:N/VC:N/VI:N/VA:H/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

3.6

Exploitability

2.8

REFERENCES

CVE-2026-66421

SUMMARY

OpenClaw Dashboard contains a stored cross-site scripting vulnerability that allows unauthenticated remote attackers to execute arbitrary JavaScript in the administrator's browser session by injecting HTML markup into agent transcript messages processed through the sessions API. Attackers can craft a message containing inline event handler payloads such as an img tag with an onerror attribute within the 60-character rendering budget, which is stored in the session transcript and interpolated unsanitized into innerHTML on the default landing page, allowing theft of session tokens and unauthorized calls to authenticated administrative endpoints including agent instruction file modification.

Published

Date2026-07-30

Updated

Date2026-07-30

RISK INFORMATION (Score: 9.3)

cvss3

Base Score: 9.3

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:R/S:C/C:H/I:H/A:N

cvss4

Base Score: 8.8

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:P/PR:N/UI:P/VC:H/VI:H/VA:N/SC:H/SI:H/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

5.8

Exploitability

2.8

REFERENCES

CVE-2026-66420

SUMMARY

MeshCentral 1.1.21 contains a cross-site WebSocket hijacking protection bypass vulnerability that allows unauthenticated remote attackers to hijack authenticated administrator sessions by exploiting an unconditional early return in the CheckWebServerOriginName() function within webserver.js when self-signed certificates are in use. Attackers can open cross-origin WebSocket connections to any of the twelve WebSocket endpoints, send crafted action commands to exfiltrate the server sessionKey used to sign session cookies, forge session tokens as arbitrary users, and gain full remote control of all managed devices governed by the MeshCentral instance.

Published

Date2026-07-30

Updated

Date2026-07-30

RISK INFORMATION (Score: 8.8)

cvss3

Base Score: 8.8

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:R/S:U/C:H/I:H/A:H

cvss4

Base Score: 8.6

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:A/VC:H/VI:H/VA:H/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

5.9

Exploitability

2.8

REFERENCES

CVE-2026-66369

SUMMARY

The GOOSE parser contains an off-by-one boundary-handling flaw that can be triggered by a single unauthenticated Layer-2 multicast frame on the process bus. When specific GOOSE message fields are processed, the parser advances its internal buffer position incorrectly, resulting in a heap out-of-bounds read. On affected platforms, this condition reliably terminates the subscriber process and causes a denial-of-service.

Published

Date2026-07-30

Updated

Date2026-07-30

RISK INFORMATION (Score: 6.5)

cvss3

Base Score: 6.5

Complexity: LOW

CVSS:3.1/AV:A/AC:L/PR:N/UI:N/S:U/C:N/I:N/A:H

cvss4

Base Score: 7.1

Complexity: LOW

CVSS:4.0/AV:A/AC:L/AT:N/PR:N/UI:N/VC:N/VI:N/VA:H/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

3.6

Exploitability

2.8

REFERENCES

CVE-2026-66364

SUMMARY

The GOOSE payload parser contains a boundary handling flaw that can be triggered by a single unauthenticated Layer 2 multicast frame on the process bus. When processing specific payload fields, an attacker controlled inner element length may exceed its enclosing length, causing the parser to over read by one byte. This out-of-bounds read reliably terminates the subscriber process, resulting in a denial-of-service condition.

Published

Date2026-07-30

Updated

Date2026-07-30

RISK INFORMATION (Score: 6.5)

cvss3

Base Score: 6.5

Complexity: LOW

CVSS:3.1/AV:A/AC:L/PR:N/UI:N/S:U/C:N/I:N/A:H

cvss4

Base Score: 7.1

Complexity: LOW

CVSS:4.0/AV:A/AC:L/AT:N/PR:N/UI:N/VC:N/VI:N/VA:H/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

3.6

Exploitability

2.8

REFERENCES

Loading…

API

Access Data Using Our API

Get company history

curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'

Try It API Documentation Rapid

MEASURE

What Do We Measure ?

Incident

Finding

Grade

Digital Assets

Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.

These are some of the factors we use to calculate the overall score:

Network SecurityIdentify exposed access points, detect misconfigured SSL certificates, and uncover vulnerabilities across the network infrastructure.

SBOM (Software Bill of Materials)Gain visibility into the software components used within an organization to detect vulnerabilities, manage risk, and ensure supply chain security.

CMDB (Configuration Management Database)Monitor and manage all IT assets and their configurations to ensure accurate, real-time visibility across the company's technology environment.

Threat IntelligenceLeverage real-time insights on active threats, malware campaigns, and emerging vulnerabilities to proactively defend against evolving cyberattacks.

Rankiteo

By Rankiteo

★ ★ ★ ★ ★

View on G2.com

Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.

View latest plans →View all security reports →

MILESTONEG

Users
Love Us

Loading…